&nbsp;

Aug 2025

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Jul 2025

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 2024

Drug

fludarabine

Other Name(s): Fludara®

Quick Link(s):

Apr 2023

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Apr 2024

Regimen

FC

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

fludarabine,

cyclophosphamide

Quick Link(s):

Regimen Monograph

Apr 2016

Regimen

FLOX

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Adjuvant

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

FLUD

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

fludarabine

Quick Link(s):

Regimen Monograph

Apr 2016

Regimen

FU(CIV-RT)

Cancer Type:

Gastrointestinal,

Pancreas

Intent: Adjuvant, Palliative

Drugs Used:

fluorouracil

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

FCM

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2016

Regimen

FLUD+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used: